Anatomy of the Indian Pharma Industry
Senior Director, Windmill Capital | The content in this article is purely the author’s personal opinion and is for informational and educational purposes only. It should not be construed as professional financial advice and nor to be construed as an offer to buy /sell or the solicitation of an offer to buy / sell any security or financial products.
The views and opinions stated in the content belong to the author. Windmill Capital Private Limited does not uphold nor promote any of the views / opinions. | Windmill Capital Private Limited is a SEBI registered research analyst (Regn. No. INH200007645)
Anatomy of the Indian Pharma Industry
The Indian pharma industry is the world’s 3rd largest by volume, the largest supplier of generic drugs & caters to ~50% of global vaccine demands.
RBI gives liquidity access to Mutual Funds
Markets cheer RBI’s move to provide liquidity window to mutual funds during an otherwise uncertain market
Franklin Templeton winds up six funds
Nervousness due to Covid-19, coupled with Franklin MF winding up 6 funds caused markets to end in red.
Volatility indicators show signs of cooling down
Equity markets have gained for a second straight week as the government tries to combat Covid-19 fears.
Experts foresee negative economic impact
Last week’s buying spree saw markets end in green, but the economy still might take time to recover, say experts
Govt. announces ₹1.7 lakh cr relief package
Package announced to protect the poor from impacts of the 21-day nationwide lockdown.